National Institute for Health and Clinical Excellence (NICE)
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE
Draft guidance published today (22 May 2020) by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body
The positive recommendation follows consultation on NICE’s previous draft guidance which did not recommend atezolizumab. The company has agreed to provide a larger discount to the list price of the drug following a deal with NHS England & NHS Improvement.
Around 2000 people in England have triple negative breast cancer, of whom around 600 people would be eligible for treatment with atezolizumab and nab-paclitaxel.
Given by injection every 2 weeks with chemotherapy drug nab-paclitaxel, atezolizumab (also called Tecentriq and made by Roche) works by blocking the activity of a protein called PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person’s own immune cells to attack the cancer.
Atezolizumab is the first immunotherapy that specifically targets triple negative breast cancer where tumours have PD-L1 expression of 1% or more. It is given to people who have not had chemotherapy for breast cancer that has spread to other parts of the body and where surgery to remove it is not possible.
The evidence suggests that atezolizumab plus nab-paclitaxel increases the time before the disease worsens by around 2.5 months. It also suggests that atezolizumab plus nab-paclitaxel can increase overall survival by around 9.5 months.
Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE, said: “We are pleased to have been able to work with the company to resolve the issues identified by the committee in our previous draft guidance. I know that today’s announcement will be welcomed by people with this type of breast cancer as well as for their families and carers. Atezolizumab is considered to be a breakthrough treatment in an area where there are currently few options.
“The committee heard that the availability of a new treatment that increases progression-free survival compared with chemotherapy alone will give hope to patients because it is important to them to be able to maintain a good quality life for as long as possible.”
Professor Peter Johnson, NHS clinical director for cancer said: “As well as ensuring the safety of cancer patients during the pandemic, the NHS is also working hard to make sure that the best care and treatment options are available for them.
“We are delighted that we were able to strike a deal with the company to support NICE’s recommendation for atezolizumab, which will help hundreds of people with breast cancer and their families – it means that patients with triple breast cancer have a significantly better option for treatment.”
Advanced triple negative breast cancer has a significant negative impact on the quality of life of patients. It can be more aggressive than other types of breast cancer (despite accounting for only 15–20% of breast cancer cases, it accounts for 25% of deaths). The committee heard from the patient expert that the burden of the disease on the family is high, both emotionally and financially.
The cost of a course of treatment with atezolizumab is £39,981 based on treatment for 7.5 months at its full list price but the company offered the NHS a confidential discount.
NICE expects to publish its final guidance on atezolizumab for triple negative breast cancer in June 2020.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE signals commitment to greater flexibility in its evaluation of promising new health technologies and making patient access fairer20/01/2022 14:15:00
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board yesterday (19 January 2022).
Self-harm is everyone’s business, NICE says in new draft guideline19/01/2022 09:15:00
All professionals working across the health and social care system have a role to play in supporting people who self-harm and the issue should not just be seen as the responsibility of those with mental health expertise, NICE has said in a new draft guideline.
Children and young people set to benefit from new treatment for peanut allergy23/12/2021 11:05:00
Children and young people aged between 4 and 17 with a peanut allergy could be set to benefit from Palforzia, a new treatment which can help build up their tolerance to peanut, after NICE recommended its use in draft guidance published today (23 December 2021)
NICE recommends offering PrEP to people at high risk of HIV for first time20/12/2021 13:15:00
People at the highest risk of catching HIV should be offered Pre Exposure Prophylaxis (PrEP), NICE has recommended for the first time.
Over 600 people set to benefit from innovative lung cancer treatment within the Cancer Drugs Fund30/11/2021 12:15:00
More than 600 people could benefit from an innovative drug for a form of lung cancer as NICE publishes final draft guidance recommending osimertinib within the Cancer Drugs Fund
Lessons learned from the multi-agency advisory service – helping developers of AI and data-driven tech to navigate the regulatory pathway25/11/2021 11:15:00
Clíodhna Ní Ghuidhir and Rebecca Boffa outline the common challenges that developers of artificial intelligence (AI) tech face when navigating their way to the health and care market, and link to their series of articles, which provide further advice on what can be done to avoid these.
NICE creates new menu of treatment options for those suffering from depression23/11/2021 12:15:00
People with depression should make the choice on what treatment option is right for them, in discussion with their healthcare professional, NICE says in new draft guidance
NICE draft guidance recommends new treatment for spinal muscular atrophy as part of a managed access agreement22/11/2021 14:15:00
Around 1,500 people in England with the rare genetic disorder spinal muscular atrophy are set to benefit from a new treatment after NICE recently (19 November 2021) published draft guidance recommending risdiplam (also called Evrysdi and made by Roche) as part of a managed access agreement (MAA).